尽管其白血病药物达到了关键的试验目标,但Syndax制药公司库存却暴跌。 Syndax Pharmaceuticals' stock plummeted despite its leukemia drug meeting key trial goals.

Syndax制药公司的库存量下降了22.1%至16.96美元,因为其药物Revumenib显示,特定类型急性流血性白血病(AML)患者的完全恢复率为23%。 Syndax Pharmaceuticals' stock fell 22.1% to $16.96 after its drug, revumenib, showed a 23% complete remission rate in patients with a specific type of acute myeloid leukemia (AML). 尽管患者的治疗结果符合主要终点,患者的治疗缓解时间中位数为4. 7个月,但该库存下降. Despite the positive outcome meeting primary endpoints, with patients in remission for a median of 4.7 months, the stock dropped. Syndax计划在2025年上半年提交该药物的申请,预计到2024年底将核准另一种用途。 Syndax plans to submit an application for the drug in the first half of 2025 and expects approval for another use by the end of 2024.